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HIV-2 infection is mainly concentrated in West African countries with an estimate number of 
1 to 2 million infections [1-2]. As a result of socio-economic links to West African countries 
and human migration, HIV-2 infection is also found in European countries. For instance,  
HIV-2 is responsible for 4.5% of AIDS cases in Portugal [3] and has been associated with 
1.8% of new HIV infections documented in France between 2003 to 2006 [4].  
HIV-2 is known for intrinsic resistance to NNRTI, therefore best treatment options for naïve 
patients rely on boosted-PI regimens [5-6]. Based on in vitro PI sensitivity data, two effective  
treatment combinations consist of tenofovir/emtricitabine + lopinavir/ritonavir or 
zidovudine/lamivudine + darunavir/ritonavir [7]. However, high frequency of K65R and 
Q151M mutations have been reported in patients receiving NRTIs as well as multiclass drug 
resistance emergence in a cohort from Senegal [8-9]. By contrast, emerging data from HIV-2 
integrase sequences coming from naïve patients show no major mutations to integrase 
inhibitors, providing an opportunity of treatment for HIV-2 infected patients [10].   
Key mutations sites conferring resistance to drug classes are not fully shared by HIV-1 and 
HIV-2 viruses due to genome differences. Therefore global spread of HIV-2 epidemic can 
lead to a greater frequency of HIV-1/2 dual infections with complex drug resistance 
challenges for antiretroviral treatment options.  
Case report 
The case of a 23-year-old heterosexual man, born in Côte d’Ivoire in good health until 
October 2010 when he complained of persistent diarrhoea, fatigue and weight loss. In March 
2011 he decided to move to Switzerland for appropriate medical care. He denied previous 
HIV test, exposure to antiretroviral drugs, intravenous drug use or having had a blood 
transfusion. 
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Immunovirological assessment  
The positive antibody result of a fourth generation HIV screening test (HIV Ag/Ab Combo 
Assay, COBAS ELECSYS HIV combi PT, Roche Diagnostics, Rotkreuz, Switzerland ) was 
followed by an immunodot directed against HIV-1 and HIV-2 specific antigens revealing a 
strong positive antibody response (3+) in all bands (INNO-LIA HIV 1/2 Score - 
Innogenetics). Patient’s CD4+ T-cell counts were 408 cell/mm3 (25.4%) as determined by 
multiparameter flow cytometry. 
HIV-1/2 reverse transcriptase activity was 4.351 nU/ml equivalent to 82.902 copies/ml total 
viraemia, measured by product-enhanced reverse transcriptase assay [11].  At the same 
timepoint,  HIV-1 viral load was 21.000 copies/ml   (COBAS AmpliPrep/COBAS TaqMan 
version 1.0 Roche Diagnostics), demonstrating a major role of HIV-2 contribution to total 
viraemia. 
Genotypic analysis  
Results of both viruses’ genotypic analyses are summarized in table 1. Briefly, HIV-1 
analysis was performed with Virco algorithm (VirtualPhenotypeTM) as part of the routine 
HIV assessment from the Lausanne hospital. Related drug resistance mutations were assigned 
according to the IAS-USA 2011 consensus.  HIV-2 genotypic analysis was done at the 
Virology laboratory from the University Hospital of Bordeaux using primers previously 
described for amplification of Reverse transcriptase and Protease regions [12]. The obtained 
fragments were sequenced on both strands using the ABI BDV3.1 on an automated Applied 
Biosystems 3500XL DX sequencer. The sequences were identified by alignment on reference 
HIV-2 sequences and ANRS algorithm V20 (French National Agency for AIDS Research, 
HIV-1 genotypic drug resistance interpretations algorithms, version 20, updated 12 July 2011, 
France) was used for interpretation of HIV-2 resistance mutations. The patient was confirmed 
to be infected with HIV-1 (CRF02_AG) and HIV-2 (clade A). The HIV-1 virus harbored 
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resistance mutation M184V to NRTIs and V90I, a secondary mutation implicated in the 
development of resistance to etravirine. Whereas HIV-2 virus carried also resistance to NRTIs 
with mutations K65R and D67N as well as a naturally expected resistance to NNRTI drugs. 
Different polymorphisms at related PI drug resistance positions were observed for both 
viruses.  
Table 1  
Primary drug resistance mutations and related polymorphisms present in a dual HIV-
1/2 infected individual.    
Viral clade  NRTI  
mutations 
NNRTI 
mutations 
PI 
mutations  
Integrase 
mutations  
HIV-1     
CRF02_AG M184V V90wt/I V11I, K20I, 
M36I, 69K, 
89I 
NONE  
HIV-2     
A K65R, D67N V106I, 
E138A, 
V179I, 
Y181V, 
Y188L, 
G190A 
L10V, G16E, 
V32I, L33V, 
M36I, M46I,     
I47V, 69K, 
89I  
N/A  
Note CRF: HIV-1 circulating recombinant form. NNRTI: nonnucleoside analogue reverse 
transcriptase inhibitors. NRTI: nucleoside and nucleotide analogue reverse transcriptase 
inhibitors. PI: protease inhibitors. N/A: not available. 
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Discussion 
To the best of our knowledge this is the first report of multiclass primary drug resistance in 
the context of HIV-1/2 dual infection. This case underlines the pitfall of dual HIV infection 
with two different patterns of resistance to NRTIs as demonstrated in the genotypic resistance 
tests performed on both viruses. Surprisingly, mutation M184V is traced in this patient after 
several months of HIV infection onset according to epidemiological, clinical and 
immunological information. Based on the knowledge we have from HIV-1 infection, NRTI 
mutation M184V becomes quickly undetectable when transmitted as primary resistance in 
naïve patients. However, we ignore if a different kinetic applies for resistant viral populations 
in the context of HIV-1/2 co-infection. Furthermore, this report underscores the limitations of 
current treatment options in the context of circulating HIV-1/2 dual infections despite the 
irrefutable progress achieved in HIV-1 treatment. Also it highlights the pertinence of guiding 
HIV-1/2 dual infection treatment choice on genotypic analysis of both viruses.  To end, it 
brings awareness on the need of new drugs to treat multiclass resistant HIV-1/2 infections. 
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